Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Biocon failed to provide critical information about proposed denosumab product, Amgen claims | Company expects ‘sales erosion’ of Prolia and XGEVA in 2025 driven by biosimilar competition | Sandoz launched interchangeable versions of bone drugs last month following settlement in 2024.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Americas

Settled expectations, the six-year rule, and developments in USPTO policy

6 November 2026 Uncertainty over whether a patent can be challenged through inter partes review at the USPTO has only increased since the discretionary denial policy was introduced, so how should companies plan? Mauricio Uribe and Maria Anderson of Davis Wright Tremaine explain.

Americas

Court upholds $83m sequencing verdict and sets royalty rate

17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.

Americas

Amgen and subsidiary dealt $20m blow over rodent antibody tech

15 June 2026 Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.